question: Compared to sorafenib what was the result of axitinib on Median progression-free survival?
context: In the Japanese subgroup analysis, IRC-assessed median PFS with axitinib was 12.1 months (95% CI 8.6 to not estimable) compared with 4.9 months (95% CI 2.8–6.6) with sorafenib (HR 0.390; 95% CI 0.130–1.173; P = 0.0401, stratified one-sided log-rank test) (Fig. 1B, Table 3).